NEW YORK, January 6, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting UnitedHealth Group Inc. (NYSE: UNH), AbbVie Inc. (NYSE: ABBV), Eli Lilly & Co. (NYSE: LLY), Actavis plc (NYSE: ACT), and Humana Inc. (NYSE: HUM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

UnitedHealth Group Inc. Research Report

On December 23, 2013, UnitedHealth Group Inc. (UnitedHealth Group) announced that it will release financial results for Q4 2013 and full-year 2013 on January 16, 2014, before the market opens. UnitedHealth Group added that President and CEO Stephen J. Hemsley will host a teleconference at 8:45 a.m. ET. The Company further noted that the live webcast and replay of the call will be accessible through the Investors page on its website. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73e5_UNH

--

AbbVie Inc. Research Report

On December 20, 2013, AbbVie Inc. (AbbVie) announced that its participation in the 32nd Annual J.P. Morgan Healthcare Conference on January 15, 2014. AbbVie informed that Bill Chase, Executive Vice President and Chief Financial Officer, will present on behalf of the Company at 11:00 a.m. CT. AbbVie further added that the live audio webcast and replay of the question and answer session is accessible through its Investor Relations website. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/273c_ABBV

--

Eli Lilly & Co. Research Report

On December 20, 2013, Eli Lilly and Company (Lilly) and Boehringer Ingelheim together announced that the US Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an investigational basal (long-acting) insulin. Lilly informed that the LY2963016 is an insulin glargine product developed for the treatment of patients with type 1 and type 2 diabetes. The Company added that the NDA was filed under the 505(b)(2) regulatory pathway, allowing the FDA to refer previous findings of safety and efficacy data for an already-approved insulin glargine product, in addition to studies of LY2963016. Lilly further stated that apart from comparative pharmacokinetic and pharmacodynamic studies, the NDA submission for LY2963016 includes results from Phase III studies, which were conducted in patients with type 1 and type 2 diabetes, using a currently marketed insulin glargine product as the active comparator. Gwen Krivi, Ph.D., Vice President, Lilly Diabetes Product Development, said, "The US regulatory submission for our new insulin glargine product demonstrates our progress in bringing another option to the millions of Americans with diabetes who require long-acting insulin as an integral part of their treatment plan. This submission of the NDA for this product helps us realize the goal of the Lilly-Boehringer Ingelheim Diabetes alliance, which is to leverage our combined expertise to develop important treatments for people with diabetes." The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/977d_LLY

--

Actavis plc Research Report

On December 24, 2013, Actavis plc (Actavis) confirmed that its subsidiary, Warner Chilcott Company LLC (Warner Chilcott), has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for the approval to market Ethinyl Estradiol and Etonogestrel Vaginal Ring, 0.015 mg/24 hour and 0.12 mg/24 hour. Actavis informed that its ANDA product is a generic version of Merck & Co.'s (Merck) NuVaRing (R), an estrogen/progestin combination hormonal contraceptive indicated for use by women to prevent pregnancy. Actavis added that Merck Sharp & Dohme B.V. filed a suit against Warner Chilcott on December 24, 2013, under the provisions of the Hatch-Waxman Act, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent No. 5,989,581. The Company noted that this resulted in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plantiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. The Full Research Report on Actavis plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4997_ACT

--

Humana Inc. Research Report

On December 19, 2013, Humana Inc. (Humana) and Healthsense jointly announced that the member enrollment in a remote monitoring pilot program has been completed with the help of Humana Cares / Senior Bridge, Humana's national chronic care management division, which identified and enrolled 100 Humana Medicare Advantage members in Florida, North Carolina, South Carolina, Kentucky, and West Virginia in the "Activities of Daily Living" (ADL) in-home, year-long Telehealth pilot aimed at helping members remain independent in their homes. Humana informed that this pilot will measure the impact of in-home sensors and remote monitoring technology on improving health outcomes and reducing frailty and fall-related hospital admissions for Medicare members with chronic health conditions. Humana added that the Healthsense eNeighbor(R) remote monitoring system reports changes in the member's normal patterns of movement and activity to Humana care managers through the use of in-home sensors that track routine daily activities (sleeping, eating, physical activity, and toileting). The Full Research Report on Humana Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/496b_HUM

----

EDITOR NOTES: 


        
        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human
          and are prone to make mistakes. If you notice any errors or omissions, please notify
          us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
          pubco@EquityNewsNetwork.com.
        5) For any urgent concerns or inquiries, please contact us at
          compliance@EquityNewsNetwork.com.
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner